besifloxacin
Trade name: besivance
Approved
May 28, 2009
Besifloxacin (INN/USAN) is a fourth-generation fluoroquinolone antibiotic. The marketed compound is Besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003. Besifloxacin is indicated in the treatment of bacterial conjunctivitis caused by sensitive germs, as well as in the prevention of infectious complications in patients undergoing laser therapy for the treatment of cataracts. Besifloxacin inhibits bacterial DNA gyrase and topoisomerase IV and has a broad spectrum of bactericidal activity against strains commonly isolated from patients with bacterial conjunctivitis. In addition, some exploratory in vitro data suggest that Besifloxacin inhibits cytokine formation in human corneal epithelial cells and monocytes, but the relevance of this finding to therapeutic efficacy is unknown. — NCATS
Clinical trial activity
21 trials · 14 clinical orgs · 1 marketing orgs
Earliest trial started Dec 1, 2004 (NCT00622908)
Timeline
2000s
- Jan 1, 2004
Bausch & Lomb — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2006
Bausch & Lomb — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2006
Bausch & Lomb — Earliest Phase 3 Sponsor(trial)
- May 28, 2009
Bausch & Lomb — Earliest FDA Approval
- May 28, 2009
Bausch & Lomb — NDA Organization
Indications
Approved for
Studied for
Mechanism of action
- Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
Broad spectrum
- Bacterial DNA gyraseINHIBITOR
Bacterial DNA gyrase inhibitor
Approval history
- approvedMay 28, 2009
Chemistry & pharmacology
SMILES
N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1- Mol. weight
- 393.85 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL1201760 ↗
- WikipediaBesifloxacin ↗
- NCATSBFE2NBZ7NX ↗
- ChEMBLCHEMBL1201761 ↗
Also known as
- 7-(3-aminohexahydro-1h-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
- 7-((3r)-aminohexahydro-1h-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin
- besifloxacin hcl
- besifloxacin hcl
- besifloxacin hcl
- besifloxacin hydrochloride
- besifloxacin hydrochloride
- besifloxacin hydrochloride
- besifloxacin hydrochloride
- besifloxacin hydrochloride
- besifloxaxin
- besivance
- besivance
- besivance
- besivance
- besivance
- besivance
- bol-303224-a
- bol-303224-a
- bol-303224-a
- bol-303224-a
- bol-303224-a
- ss734
- ss-734
- ss-734
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04542759 | Phase 1 | Jan 31, 2017 | University of Valencia |
| NCT02717871 | Phase 3 | Mar 1, 2016 | University of Geneva |
| NCT02497365 | N/A | Sep 1, 2015 | McGill University |
| NCT01928693 | Phase 2 | Jul 1, 2013 | Bausch & Lomb, Cornea Consultants Of Nashville, SCRI Development Innovations |
| NCT01740388 | Phase 3 | Feb 1, 2013 | Bausch Health Companies, Bausch & Lomb |
| NCT01431170 | Phase 1 | Sep 1, 2011 | Bausch & Lomb, Rutgers University |
| NCT01478256 | Phase 4 | Aug 1, 2011 | Bausch & Lomb, John, George, M.D. |
| NCT01296542 | Phase 4 | May 31, 2011 | Bucci Laser Vision Institute |
| NCT01296191 | Phase 4 | May 1, 2011 | Bucci Laser Vision Institute |
| NCT01330355 | Phase 3 | May 1, 2011 | Bausch Health Companies, Bausch & Lomb |
| NCT01455233 | Phase 4 | Sep 1, 2010 | Bausch & Lomb, Ophthalmology Associates, St Louis, Ophthalmology Consultants, Ltd. |
| NCT01175590 | Phase 3 | Jun 1, 2010 | Bausch & Lomb |
| NCT00972777 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2009 | Bausch & Lomb |
| NCT00924729 | Phase 4 | Sep 1, 2009 | Johns Hopkins University |
| NCT00905762 | Phase 1 | Mar 1, 2009 | Bausch & Lomb |
| NCT00824070 | Phase 1 | Feb 1, 2009 | Bausch & Lomb, Ophthalmic Consultants of Long Island |
| NCT01120418 | Phase 1 | May 1, 2007 | Bausch & Lomb |
| NCT00407589 | Phase 1 | Oct 1, 2006 | Bausch & Lomb |
| NCT00347932 | Phase 3 | Jun 1, 2006 | Bausch & Lomb |
| NCT00348348 | Phase 3 | Jun 1, 2006 | Bausch & Lomb |
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bausch & Lomb | For profit | 15 | 11 | 4 | 2004 |
| Bausch Health Companies | For profit | 2 | 0 | 1 | 2011 |
| Bucci Laser Vision Institute | Academic/Hospital | 2 | 2 | 1 | 2011 |
| Cornea Consultants Of Nashville | Academic/Hospital | 1 | 1 | 1 | 2013 |
| John, George, M.D. | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| McGill University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Ophthalmic Consultants of Long Island | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Ophthalmology Associates, St Louis | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Ophthalmology Consultants, Ltd. | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Rutgers University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2013 |
| University of Geneva | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Valencia | Academic/Hospital | 1 | 1 | 1 | 2017 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bausch & Lomb | For profit | NDA | May 28, 2009 |